UPDATE: Barrington Research Initiates Coverage on Rosetta Genomics Ltd. with Outperform Rating, $7 PT on Good Market Position

In a report published Wednesday, Barrington Research analyst Charley R. Jones initiated coverage on

with an Outperform rating and $7.00 price target. In the report, Barrington Research noted, “We are initiating coverage of Rosetta Genomics with an OUTPERFORM investment rating and a $7.00 price target. Rosetta Genomics (ROSG) is a molecular diagnostic company focused on the development and commercialization of diagnostic tests for cancers and other diseases based on its unique and proprietary microRNA platform. Rosetta was one of the first companies to recognize the potential of microRNAs and between the intellectual property (IP) it has licensed from other early thought leaders out of academia and its own development work/patent filings, ROSG has developed one of the most extensive patent portfolios around the use of microRNAs for diagnostic purposes.” Rosetta Genomics Ltd. closed on Tuesday at $4.03.